chevron_leftBack
As of 13 June 2026, Xilio Therapeutics, Inc. has a market cap of $44.81M USD, ranking #31366 globally and #4537 in the United States.
It ranks #2836 in the Healthcare sector, and #989 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$44.81MUSD
Enterprise Value
-$86.06MUSD
Revenue (TTM)
$43.77MUSD
EBITDA (TTM)
-$40.44MUSD
Net Income (TTM)
-$35.04MUSD
EBITDA Margin
-92%
Profit Margin
-80%
PS Ratio
1.0
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Rene Russo
open_in_new
Employees
76
Founded
2016
IPO
22 Oct 2021
Website
xiliotx.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -9.9% | -7.8% | -11% | -33% | -30% |
News
Loading...
XLO Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
XLO
ISIN: US98422T2096
Shares Out.:
Shares Outstanding:
6.575M1
Shares Float:
2.88M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.75 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
2M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
1M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
805K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
611K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
333K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
262K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
717K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
644K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
613K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
406K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
246K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
242K%
80.96B GBP
|
14.6
|
chevron_leftBack